News

News

New Pathology Faculty Member in the Penn Sarcoma Program

April 16, 2015

The Penn Sarcoma Program and the Department of Pathology and Laboratory Medicine are pleased to announce the addition of Karin Eisinger, PhD, as an Assistant Professor (tenure track) on the standing faculty starting this month. Dr. Eisinger has a B.S. in Biology from the University of Miami and a Ph.D. in Microbiology with an emphasis in Cancer Research from the University of Virginia. Her graduate thesis focused on discovering the role of Ser/Thr kinase, RSK2, in cellular responses to oxidative stress in cancer. Dr. Eisinger completed a postdoctoral fellowship in Dr. M. Celeste Simon's laboratory at the University of Pennsylvania where she examined the role of hypoxia and Hypoxia Inducible Factors (HIFs) in sarcomagenesis and in metastasis via modification of the extracellular matrix.

Key publications include:

1. Eisinger-Mathason, T.S.K. , Andrade, J., Groehler, A.L., Muratore-Shroeder, T.L., Smith, J.A., Clark, D.E., Pasic, L., Shabanowitz, J., Hunt, D.F., Macara, I.G., Lannigan, D.A., Co-dependent functions of RSK2 and the apoptosis promoting factor, TIA-1, in stress granule assembly and cell survival. Molecular Cell 31(5) pp. 722 – 736. 2008

2. Eisinger-Mathason, T.S.K and Simon, M.C. HIF1 partners with FoxA2, a neuroendocrine-specific transcription factor, to promote tumorigenesis. Cancer Cell 18(1) pp.3-4. 2010

3. Eisinger-Mathason, T.S.K., Zhang, M., Qiu, Q., Skuli, N., Nakazawa, M.S., Karakasheva, T., Mucaj, V., Shay, J.E.S., Stangenberg, L., Sadri, N., Puré, E., Yoon, S.S., Kirsch, D.G., Simon, M.C. Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discovery 3(10) pp.1190-1205. 2013

4. Eisinger-Mathason, T.S.K., Mucaj, V., Biju, K.M., Nakazawa, M.S., Cash, T.P., Yoon, S.S., Park, K.M., Skuli, N., Gerecht, S., Simon, M.C Deregulation of the Hippo pathway in soft tissue sarcoma promotes FOXM1 expression and tumorigenesis. In Press, Proceedings of the National Academy of Sciences

The vision of the Penn Sarcoma Program has a foundation in scientific discovery and molecular analysis of all sarcomas. Clinical trials based on novel Penn findings in the laboratory and patterns noted from the molecular analysis will allow personalized treatment based on individual tumor targets. Along with a cohesive, coordinated recognized clinical team, this will lead to improved patient survival.

Dr. Eisinger is an exceptional young scientist who has recently focused exclusively on basic mechanisms and translational discoveries related to sarcoma. She is an example of true talent "grown" from within the Penn system. She will participate in all scientific aspects of the Sarcoma program in addition to building bridges to the clinical arm of the initiative. Dr. Eisinger’s laboratory will be in the AFCRI, and she will collaborate with clinicians and scientists in Pathology and Laboratory Medicine, at the University of Pennsylvania Medical School, Veterinary School and the Children’s Hospital of Philadelphia.